Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15

29Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

Objectives: Temocillin is a 6a-methoxy derivative of ticarcillin that is resilient to ESBLs. Prospective data about its in vivo activity remain scarce. Our aims were: (i) to evaluate the activity of temocillin in a urinary tract infection (UTI) model due to ESBL-producing Escherichia coli and compare it with that of imipenem; and (ii) to define in vivo susceptibility breakpoints. Methods: Mice were infected with a susceptible E. coli CFT073-RR or its transconjugant (CFT073-RR Tc) harbouring a blaCTX-M-15-carrying plasmid, using an ascending UTI model. Therapeutic regimens were chosen in order to reproduce percentage of time of free drug concentrations above MIC (fT.MIC) obtained in humans with standard regimens of temocillin (200 mg/kg every 2 h for 2 g every 12 h) or imipenem (100 mg/kg every 2 h for 1 g every 8 h). Additional regimens of temocillin (200 mg/kg every 4 and 6 h) with reduced fT.MIC were studied. Results: MICs of temocillin and imipenem were 4/8 and 0.5/0.5 mg/L, for CFT073-RR and CFT073-RR Tc, respectively. In vivo, when given every 2 h (fT.MIC1/482% and 70%), temocillin was bactericidal and as effective as imipenem in kidneys against both strains without selecting resistant mutants. Temocillin remained active even when given every 4 h, generating an fT.MIC of 41% and 35%, which corresponded to a breakpoint of 16 mg/L in humans with the standard regimen. Conclusions: Our observations support the consideration of a standard regimen of temocillin as an alternative to carbapenems for the treatment of UTI due to CTX-M-producing E. coli strains with an MIC of 16 mg/L or less.

References Powered by Scopus

Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America

4156Citations
N/AReaders
Get full text

Global spread of carbapenemase producing Enterobacteriaceae

1935Citations
N/AReaders
Get full text

Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern

1761Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Treatment of infections caused by extended-spectrum-beta-lactamase-, ampC-, and carbapenemase-producing enterobacteriaceae

517Citations
N/AReaders
Get full text

Mechanisms of antimicrobial resistance in Gram-negative bacilli

332Citations
N/AReaders
Get full text

What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review

132Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Soubirou, J. F., Rossi, B., Couffignal, C., Ruppé, E., Chau, F., Massias, L., … Fantin, B. (2014). Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15. Journal of Antimicrobial Chemotherapy, 70(5), 1466–1472. https://doi.org/10.1093/jac/dku542

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 15

60%

Researcher 8

32%

Professor / Associate Prof. 2

8%

Readers' Discipline

Tooltip

Medicine and Dentistry 11

52%

Pharmacology, Toxicology and Pharmaceut... 4

19%

Agricultural and Biological Sciences 3

14%

Biochemistry, Genetics and Molecular Bi... 3

14%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 28

Save time finding and organizing research with Mendeley

Sign up for free